Famous Patents
The first commercial microwave oven was nearly 6 feet tall and weighed in at 750 pounds.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8071544 | Crystallized recombinant human growth factor formulations Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins. ... | 12/06/2011 |
| 8008454 | Fusion protein having the enhanced in vivo activity of erythropoietin The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for... | 08/30/2011 |
| 7932364 | Compositions and methods for the preparation of human growth hormone glycosylation mutants The present invention relates to mutants of human growth hormone, which contain newly introduced N-linked or O-linked glycosylation site(s), such that these recombinantly produced polypeptides have glycosylation patterns distinctly different from that of the natural... | 04/26/2011 |
| 7910547 | Tissue regeneration method The invention relates to the use of haematopoietic growth factors, in particular erythropoietin (EPO) and thrombopoietin (TPO), or derivatives, analogues or parts thereof, for promoting structural tissue regeneration. ... | 03/22/2011 |
| 7649084 | Recombinant glycoproteins related to feline thyrotropin Amino acid sequences of feline thyrotropin and polynucleotide sequences encoding feline thyrotropin are provided, as well as methods of making and using said sequences. ... | 01/19/2010 |
| 7553940 | Long-acting EPO polypeptides and derivatives thereof and methods thereof A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an EPO peptide are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention a... | 06/30/2009 |
| 7442684 | Long-acting hormone and growth factor compositions and uses thereof This invention provides VEGF-FSH compounds having increased serum half-lives relative to either native VEGF or FSH, in which both VEGF and FSH are biologically active. This invention also provides related compositions and methods for increasing fertility, egg produc... | 10/28/2008 |
| 7442376 | Glycoprotein hormone compositions containing two β subunits Forms of differentially acting glycoprotein hormones are disclosed. These compositions are of the formula β1-(linker1)m-α-(linker2)n-β2; (1) β1-(linker1 | 10/28/2008 |
| 7439063 | Neuroprotective synergy of erythropoietin and insulin-like growth factors The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pa... | 10/21/2008 |
| 7431921 | Interferon beta-like molecules The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least o... | 10/07/2008 |
| 7432051 | Erythropoietin and erythropoietin receptor expression in human cancer The present invention relates to the elucidation of the role of erythropoietin and the erythropoietin receptor in the development and progression of certain solid tumors, including those found in breast, cervical, uterine, ovarian, prostate and brain cancer. ... | 10/07/2008 |
| 7427486 | Mullerian inhibiting substance levels and ovarian response Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and ser... | 09/23/2008 |
| 7423139 | High level expression of recombinant human erythropoietin having a modified 5′-UTR The present invention provides an expression construct capable of producing high levels of erythropoietin in mammalian cells. More particularly, the expression construct includes an erythropoietin coding region fused to a unique 5′-UTR sequence and a truncated 3... | 09/09/2008 |
| 7410941 | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the fu... | 08/12/2008 |
| 7388081 | Method for manufacturing glycoproteins having human-type glycosylation The present invention provides a method for manufacturing a glycoprotein having a human-type sugar chain comprising a step in which transformed plant cell is obtained by introducing to a plant cell the gene of glycosyltransfetase and the gene of an exogenous glycopr... | 06/17/2008 |
| 7381804 | G-CSF analog compositions and methods The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules. ... | 06/03/2008 |
| 7378392 | Bone and cartilage inductive proteins Purified cartilage and/or bone inductive proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair. ... | 05/27/2008 |
| 7358341 | Beta-like glycoprotein hormone polypeptide and heterodimer Novel β10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing β10 polypeptides and heterodimeric forms thereof, spec... | 04/15/2008 |
| 7345019 | Modulation of excitable tissue function by peripherally administered erythropoietin Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the fu... | 03/18/2008 |
| 7332320 | Protease producing an altered immunogenic response and methods of making and using the same The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants... | 02/19/2008 |
| 7317095 | Mutant glycoproteins The inventors have designed novel FSH mutants with increased glycosylation and longer half-lives for use in inducing folliculogenesis in human patients. The use of a FSH mutant preparation of the invention permits the use of lower cumulative doses of FSH to achieve ... | 01/08/2008 |
| 7309687 | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the fu... | 12/18/2007 |
| 7304150 | Methods and compositions for the prevention and treatment of anemia Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to ob... | 12/04/2007 |
| 7304031 | Methods and means for producing proteins with predetermined post-translational modifications Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell i... | 12/04/2007 |
| 7300915 | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain Erythropoietin (Epo), a member of the cytokine superfamily, is a pluripotent molecule that is involved in a number of signal transduction pathways that include the stimulation of the production of red blood cells and the protection of the central nervous system from... | 11/27/2007 |
| 7268110 | Agents for preventing and treating thrombocytopenia Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient. ... | 09/11/2007 |
| 7262177 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which does not comprise a naturally occurring am... | 08/28/2007 |
| 7262166 | Chemically modified novel erythropoietin stimulating protein compositions and methods The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP). ... | 08/28/2007 |
| 7256262 | Secreted and transmembrane polypeptides and nucleic acids encoding the same The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 08/14/2007 |
| 7250490 | PRO1480 polypeptides The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 07/31/2007 |
| 7250493 | FC fusion proteins of human erythropoietin with increased biological activities Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc var... | 07/31/2007 |
| 7241577 | Mullerian inhibiting substance levels and ovarian response Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and ser... | 07/10/2007 |
| 7238344 | Interferon-β variants and conjugates The present invention provides new interferon β conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis. ... | 07/03/2007 |
| 7217689 | Glycosylation analogs of erythropoietin Erythropoietin analogs having at least one additional site for glycosylation, or a rearrangement of at least one site for glycosylation are disclosed. The invention also relates to DNA sequences encoding said erythropoietin analogs, and recombinant plasmids and host... | 05/15/2007 |
| 7211253 | Erythropoietin forms with improved properties The invention relates to novel modified erythropoietin (EPO) forms such as fusion proteins comprising a Fc portion of an Ig molecule and a target molecule having the biological activity of EPO. By selective altering of the amino acid sequences of the erythropoietin ... | 05/01/2007 |
| 7202208 | Erythropoietin composition The present invention relates to a liquid pharmaceutical composition consisting essentially of an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about... | 04/10/2007 |
| 7198954 | Methods for predicting pregnancy outcome in a subject by hCG assay The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early ... | 04/03/2007 |
| 7196060 | Method to enhance hematopoiesis The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which... | 03/27/2007 |
| 7173113 | Long-acting hormone and growth factor compositions and uses thereof This invention provides VEGF-FSH compounds having increased serum half-lives relative to either native VEGF or FSH, in which both VEGF and FSH are biologically active. This invention also provides related compositions and methods for increasing fertility, egg produc... | 02/06/2007 |
| 7169754 | Erythropoietin composition The present invention relates to a liquid pharmaceutical composition comprising an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0, and optio... | 01/30/2007 |
